IP Library Granted Patent US 11,441,122
Granted Patent B2
US 11,441,122 · App. 16/753,522 · Granted Sep 13, 2022

Regulatory T cell epitopes

Inventors: William Martin (Providence, RI); Amy S. Rosenberg (Silver Spring, MD)
Assignees: EpiVax Inc.; The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
C12N5/0637C07K14/52A61K38/00C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,441,122
App. No.
16/753,522
Granted
Sep 13, 2022
Kind
B2
Abstract

The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.

Claims (9)

1. A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides, wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

2. The method of claim 1 , wherein the T-cell epitope composition further comprises at least one isolated T-cell epitope polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-14.

3. The method of claim 1 , wherein the T-cell epitope composition further comprises an effective amount of one or more antigens and/or allergens.

4. The method of claim 1 , wherein the immune suppressive effect is mediated by natural regulatory T cells.

5. The method of claim 1 , wherein the immune suppressive effect is mediated by adaptive regulatory T-cells.

6. The method of claim 1 , wherein the T-cell epitope composition suppresses an effector T-cell response.

7. The method of claim 6 , wherein the T-cell epitope composition suppresses a cytokine secretion of effector T-cells.

8. The method of claim 1 , wherein the T-cell epitope composition suppresses a helper T-cell response.

9. The method of claim 1 , wherein the T-cell epitope composition suppresses a B-cell response.

Assignments (3)
SECURITY INTEREST Recorded Mar 31, 2026
From: EPIVAX, INC.
To: ESCALATE CAPITAL V, LP
Reel/Frame 074239/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: MARTIN, WILLIAM D.
To: EPIVAX, INC.
Reel/Frame 056354/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: ROSENBERG, AMY
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 056355/0090 →
Continuity (4)
Provisional Application 62729792 · Sep 11, 2018
Provisional Application 62568630 · Oct 5, 2017
Provisional Application 62568625 · Oct 5, 2017
Related Publication 20200308542A1 · Oct 1, 2020